Lightspeed Venture and Redpoint Ventures, two venture capital firms, led a $150m investment in Abridge, a medical conversation AI startup, with participation from IVP, Spark Capital, Union Square Ventures, Bessemer Venture Partners, Wittington Ventures, Mass General Brigham, Kaiser Permanente Ventures and CVS Health Ventures. “Abridge has set new standards for quality and responsible deployment of generative AI in health systems across the U.S., cementing it as the industry’s most trusted AI platform. Abridge stands out for their innovation in all facets of product development. CTO Zack Lipton, a widely cited Associate Professor at Carnegie Mellon and pioneer in responsible AI research, has assembled the strongest research team in healthcare AI. They have set new expectations for transparency and verification with their evidence extraction technology, and raised the bar for both note quality and evaluation methodology,” Sebastian Duesterhoeft, Lightspeed Venture Partner.